与高级别浆性癌相比，卵巢和腹膜的低级别浆性癌是一种罕见的上皮性卵巢癌类型，对化疗不敏感，主要影响年轻女性，其中许多人要经历多年无效治疗和低质量生活。该病的发病机制和治疗仍未完全了解。然而，最近在疾病的分子特征和对低级别浆性癌具有活性的新型靶向治疗的鉴定方面取得的进展，给改善预后带来了希望。为了更新临床医生有关最新的科学和临床试验进展，并讨论与低级别浆性癌诊断和治疗相关的未解答问题，一组专家于2022年10月召开了一次研讨会，制定了一份共识文件，涵盖病理学、转化研究、流行病学和风险、临床管理以及正在进行的研究。此外，还讨论了患者的观点。这个专家小组制定的建议-在这份共识文件中呈现-将指导各个环境中的从业者有关低级别浆性癌患者的临床管理，并讨论改善研究和患者护理的未来机会。© IGCS and ESGO 2023. 在CC BY-NC许可下可重新使用。不可进行商业再利用。由BMJ出版。

Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel-presented in this consensus document-will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.© IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.